Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of BGT-002 tablets in primary hypercholesterolemia
CTR20240756Phase 2Completed
- Sponsor
- Burgeon Therapeutics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BGT-002 in hypercholesterolemia, sponsored by Burgeon Therapeutics. Started Mar 2024; status: completed.
02
Drugs
BGT-002
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on CTR20240756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240756.